A three‑judge panel of the 5th U.S. Circuit Court of Appeals in New Orleans heard arguments on Wednesday over whether the prescribing rules for mifepristone – the drug that initiates the most common medication abortion – should be tightened. The case is part of a broader effort by anti‑abortion advocates, many of whom are strong supporters of President Trump, to limit the flow of abortion pills into states that have enacted strict bans.
Background and plaintiffs
The lawsuit was filed by Louisiana Attorney General Liz Murrill and Rosalie Markezich, who claims she was coerced into taking abortion pills. A survey by the Society of Family Planning estimates that between 770 and 900 Louisiana women obtained abortions each month in 2025 using pills prescribed online or by out‑of‑state providers protected by “shield laws.”
Judicial composition and prior rulings
Two of the judges hearing the case were appointed by Democratic presidents Barack Obama and Joe Biden, while the third was appointed by Republican George W. Bush. Earlier this year, two other three‑judge panels on the 5th Circuit and two district courts concluded that the current FDA prescribing rules for mifepristone are too lax.
Supreme Court and FDA positions
The Supreme Court unanimously rejected a 2024 challenge to roll back mifepristone availability, not on the merits but because the anti‑abortion groups lacked legal standing. The U.S. Food and Drug Administration, which is reviewing the rules, argues that any change should come from the agency, not the courts. FDA scientists have repeatedly affirmed the safety and effectiveness of the drug.
President Trump’s latest nominee to lead the FDA, Dr. Heidi Overton, previously served as deputy director of the White House Domestic Policy Council and has publicly criticized the agency for loosening prescribing rules in 2023.
State impact and Medicaid concerns
Louisiana’s solicitor general, Benjamin Aguinaga, noted that the state is affected because some women who use the pills seek treatment for complications, and many are covered by Medicaid. Other GOP attorneys general – in Florida, Texas, Idaho, Kansas and Missouri – are also challenging the FDA’s rules.
Potential consequences
If the appeals court sides with the plaintiffs, the ruling could restore an in‑person requirement for the medication nationwide, even in states that have enacted protective shield laws. Anti‑abortion groups argue this would honor the promise of the Dobbs decision, which returned abortion regulation to the states.
Abortion‑rights advocates warn that restricting mifepristone would not end access to medication abortions; providers could shift to prescribing misoprostol alone, which alone can induce abortion in many cases.
Public opinion and political context
While most voters continue to favor legal abortion access in most circumstances, the issue remains a flashpoint in the midterm election year. Anti‑abortion supporters of President Trump are frustrated that the telehealth workaround persists, and they are pressing both the courts and the administration to act.
One judge, Stephen Higginson, questioned whether the FDA’s role should be a factor, noting that “those are state shield laws” and that the federal government has no direct involvement.
Next steps
The court ordered the FDA to provide a status update by Oct. 7, less than a month before the midterm elections. The outcome of that update and any subsequent agency action will likely be contested in further litigation.
Original reporting: Dallas TX News (HLL/CB) — read the source article.
